Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1901P - Immunomodulatory role of multi-agent therapy in thymic epithelial tumours and severe immunological dysregulation

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Margaret Ottaviano

Citation

Annals of Oncology (2020) 31 (suppl_4): S1018-S1025. 10.1016/annonc/annonc292

Authors

M. Ottaviano1, M. Giuliano2, M. Tortora3, F. Picozzi4, B. Mucci4, S. Parola4, V. Riccio4, E. Pietroluongo4, P. De Placido4, A. Vaia4, V. D'Esposito5, A.M. Malfitano5, S. Di Somma5, S. Campione6, S. Staibano6, G. Botti7, P. Formisano5, B. Daniele1, S. De Placido2, G. Palmieri3

Author affiliations

  • 1 Oncology Unit, Ospedale del Mare, 80147 - Naples/IT
  • 2 Department Of Clinical Medicine And Surgery And Crctr Rare Tumors Reference Center Of Campania Region, Università degli studi di Napoli "Federico II", Naples/IT
  • 3 Crctr Rare Tumors Reference Center Of Campania Region, Università degli studi di Napoli "Federico II", Naples/IT
  • 4 Department Of Clinical Medicine And Surgery, Università degli studi di Napoli "Federico II", Naples/IT
  • 5 Department Of Translational Medical Sciences, Federico Ii University, Naples, Italy, Università degli studi di Napoli "Federico II", Naples/IT
  • 6 Department Of Advanced Biomedical Sciences, Università degli studi di Napoli "Federico II", Naples/IT
  • 7 Department Of Pathology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli/IT
More

Resources

Abstract 1901P

Background

The association of different parathymic entities is common in thymic epithelial tumors (TETs), although only anecdotal case reports of TET patients exhibiting both pure red cell aplasia (PRCA) and Good Syndrome (GS) were described to date. We prospectively evaluated the outcomes of TET patients with PRCA and GS treated with combination therapy allowing prolonged control of TET, autoimmunity (PRCA) and immunodeficiency (GS).

Methods

From 2013 consecutive TET patients, treated at Rare Tumors Reference Center of University Federico II, underwent diagnostic work-up for GS and PRCA, in the presence of suspicious symptoms. Subjects with GS who developed also PRCA were treated with a multi-agent therapy, including long acting octreotide 30 mg i.m. every 4 weeks, prednisone 0.6-1 mg/kg/daily (tapered when reaching Hb > 13 g/dl), cyclosporine escalation dose 50 to 200 mg/daily, darbepoietin 150 mcg weekly, intravenous immunoglobulin at 500 mg/kg per day for 5 days/monthly (tapered to 30 gr every 4 weeks), cotrimoxazolo antibiotic prophylaxis. Reticulocytes, serum immunoglobulin, C reactive protein (CRP), and Hb levels were closely monitored. Immunophenotype was assessed on whole blood by 8-colour immunophenotyping kit and Treg detection kit (CD4/CD25/CD127). TET Time to progression (TET-TTP), PRCA remission (PRCA-R), as well as occurrence of life treating infections, were assessed.

Results

16 patients were included in this study. Median age was 44 years (range 33-65); male/female ratio was 1/1; the most frequent histotype was B2 thymoma (57%). Prolonged PRCA-R was observed in all but one patient, with median time to PRCA-R of 40 days. Correlation between increase of reticulocytes and circulating Treg was detected (p = 0.0003). At the time of the last follow-up, 15 patients were alive; 2 had PRCA recurrence after a median of 2 years from the initial diagnosis, one patient died for fatal medullary aplasia and 2 were hospitalized for staphylococcus pneumonitis. Median TET-TTP of 11 months was registered.

Conclusions

This is the largest series of TET patients with PRCA and GS ever reported. The proposed multi-agent therapy achieved fast and prolonged PRCA-R, prolonged TET control and low rate of life treating infectious complications.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

CRCTR Rare Tumors Reference Center of Campania Region.

Funding

Has not received any funding.

Disclosure

M. Giuliano: Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis Pharma SAS; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer Pharmaceutical Israel; Speaker Bureau/Expert testimony: Istituto Gentili; Speaker Bureau/Expert testimony: Eisai Europe Ltd; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche. B. Daniele: Advisory/Consultancy: EISAI; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Incyte; Advisory/Consultancy: Sanofi; Advisory/Consultancy: MSD; Travel/Accommodation/Expenses: Bayer; Travel/Accommodation/Expenses: BMS; Travel/Accommodation/Expenses: Sanofi; Honoraria (self): Bayer; Honoraria (self): Eisai; Honoraria (self): Ipsen; Honoraria (self): Lilly; Honoraria (self): AstraZeneca; Honoraria (self): MSD. S. De Placido: Advisory/Consultancy, Speaker Bureau/Expert testimony: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer Pharmaceuticals Israel; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis Pharma SAS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings